Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 21 studies | 33% ± 17% | |
endothelial cell | 13 studies | 28% ± 10% | |
natural killer cell | 12 studies | 24% ± 6% | |
oligodendrocyte | 12 studies | 29% ± 10% | |
astrocyte | 12 studies | 34% ± 15% | |
glutamatergic neuron | 11 studies | 47% ± 26% | |
microglial cell | 11 studies | 28% ± 11% | |
mucosal invariant T cell | 11 studies | 21% ± 6% | |
fibroblast | 11 studies | 23% ± 7% | |
GABAergic neuron | 9 studies | 43% ± 23% | |
naive B cell | 9 studies | 22% ± 5% | |
ciliated cell | 9 studies | 31% ± 12% | |
B cell | 8 studies | 21% ± 5% | |
type I pneumocyte | 8 studies | 31% ± 10% | |
adipocyte | 8 studies | 38% ± 11% | |
smooth muscle cell | 8 studies | 21% ± 7% | |
CD4-positive, alpha-beta T cell | 7 studies | 22% ± 6% | |
T cell | 7 studies | 22% ± 4% | |
CD16-negative, CD56-bright natural killer cell, human | 6 studies | 34% ± 12% | |
pericyte | 6 studies | 25% ± 9% | |
myeloid cell | 6 studies | 32% ± 11% | |
neuron | 5 studies | 32% ± 14% | |
cardiac muscle cell | 5 studies | 55% ± 14% | |
Mueller cell | 5 studies | 24% ± 6% | |
oligodendrocyte precursor cell | 5 studies | 27% ± 7% | |
regulatory T cell | 5 studies | 28% ± 8% | |
interneuron | 5 studies | 50% ± 22% | |
granule cell | 4 studies | 29% ± 9% | |
epithelial cell | 4 studies | 26% ± 10% | |
dendritic cell | 4 studies | 22% ± 3% | |
lymphocyte | 4 studies | 26% ± 11% | |
retinal rod cell | 4 studies | 26% ± 4% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 4 studies | 18% ± 3% | |
monocyte | 4 studies | 24% ± 5% | |
mature NK T cell | 4 studies | 28% ± 9% | |
GABAergic interneuron | 3 studies | 27% ± 3% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 24% ± 3% | |
mesothelial cell | 3 studies | 21% ± 6% | |
mononuclear phagocyte | 3 studies | 34% ± 14% | |
amacrine cell | 3 studies | 27% ± 9% | |
glycinergic amacrine cell | 3 studies | 25% ± 7% | |
retina horizontal cell | 3 studies | 23% ± 7% | |
retinal cone cell | 3 studies | 24% ± 8% | |
innate lymphoid cell | 3 studies | 19% ± 4% | |
ependymal cell | 3 studies | 34% ± 11% | |
alveolar macrophage | 3 studies | 31% ± 6% | |
endothelial cell of lymphatic vessel | 3 studies | 19% ± 1% | |
group 3 innate lymphoid cell | 3 studies | 34% ± 3% | |
abnormal cell | 3 studies | 24% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 3278.50 | 245 / 245 | 100% | 37.17 | 502 / 502 |
thymus | 100% | 3087.37 | 653 / 653 | 100% | 36.98 | 603 / 605 |
brain | 99% | 3027.61 | 2620 / 2642 | 100% | 32.94 | 704 / 705 |
adrenal gland | 100% | 2476.12 | 257 / 258 | 99% | 31.90 | 227 / 230 |
breast | 100% | 3515.56 | 459 / 459 | 97% | 19.81 | 1089 / 1118 |
intestine | 100% | 3942.81 | 966 / 966 | 97% | 30.11 | 509 / 527 |
stomach | 100% | 3013.21 | 359 / 359 | 95% | 29.14 | 273 / 286 |
pancreas | 96% | 1990.64 | 316 / 328 | 98% | 17.36 | 175 / 178 |
bladder | 100% | 3676.10 | 21 / 21 | 94% | 19.44 | 476 / 504 |
esophagus | 99% | 2995.41 | 1435 / 1445 | 95% | 14.00 | 173 / 183 |
uterus | 100% | 4212.79 | 170 / 170 | 93% | 13.25 | 429 / 459 |
kidney | 97% | 1436.19 | 86 / 89 | 97% | 17.34 | 870 / 901 |
lung | 99% | 3075.78 | 575 / 578 | 92% | 12.74 | 1065 / 1155 |
skin | 100% | 3875.91 | 1803 / 1809 | 87% | 13.04 | 410 / 472 |
ovary | 100% | 5632.05 | 180 / 180 | 76% | 7.41 | 327 / 430 |
liver | 91% | 1174.25 | 205 / 226 | 85% | 10.53 | 346 / 406 |
muscle | 100% | 11506.64 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 4596.83 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 100% | 3828.34 | 1202 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2631.79 | 1332 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 11.03 | 44 / 45 |
heart | 98% | 2634.72 | 840 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 18.26 | 28 / 29 |
eye | 0% | 0 | 0 / 0 | 84% | 16.16 | 67 / 80 |
peripheral blood | 47% | 545.34 | 440 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0042149 | Biological process | cellular response to glucose starvation |
GO_0072593 | Biological process | reactive oxygen species metabolic process |
GO_0098869 | Biological process | cellular oxidant detoxification |
GO_0016239 | Biological process | positive regulation of macroautophagy |
GO_1904262 | Biological process | negative regulation of TORC1 signaling |
GO_0034198 | Biological process | cellular response to amino acid starvation |
GO_1990253 | Biological process | cellular response to leucine starvation |
GO_1901031 | Biological process | regulation of response to reactive oxygen species |
GO_0071233 | Biological process | cellular response to L-leucine |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0061700 | Cellular component | GATOR2 complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0001650 | Cellular component | fibrillar center |
GO_0005634 | Cellular component | nucleus |
GO_0070728 | Molecular function | L-leucine binding |
GO_0005515 | Molecular function | protein binding |
GO_0016684 | Molecular function | oxidoreductase activity, acting on peroxide as acceptor |
Gene name | SESN1 |
Protein name | Sestrin-1 (EC 1.11.1.-) (p53-regulated protein PA26) |
Synonyms | SEST1 PA26 |
Description | FUNCTION: Functions as an intracellular leucine sensor that negatively regulates the TORC1 signaling pathway through the GATOR complex. In absence of leucine, binds the GATOR subcomplex GATOR2 and prevents TORC1 signaling. Binding of leucine to SESN2 disrupts its interaction with GATOR2 thereby activating the TORC1 signaling pathway . This stress-inducible metabolic regulator may also play a role in protection against oxidative and genotoxic stresses (By similarity). May positively regulate the transcription by NFE2L2 of genes involved in the response to oxidative stress by facilitating the SQSTM1-mediated autophagic degradation of KEAP1 . Moreover, may prevent the accumulation of reactive oxygen species (ROS) through the alkylhydroperoxide reductase activity born by the N-terminal domain of the protein (By similarity). Was originally reported to contribute to oxidative stress resistance by reducing PRDX1 . However, this could not be confirmed (By similarity). . |
Accessions | Q9Y6P5 ENST00000302071.6 [Q9Y6P5-3] ENST00000356644.7 [Q9Y6P5-1] ENST00000436639.7 [Q9Y6P5-2] |